Estrogen Replacement and Risk of Alzheimer Disease [1] (multiple letters)

JAMA

Volumn 289, Issue 9, 2003, Pages 1100-1102

  Smith, Mark A ^a   Perry, George ^a   Atwood, Craig S ^a   Bowen, Richard L ^b   Lahad, Amnon ^c   Ishay, Lev ^c   Buckwalter, J Galen ^d   Petitti, Diana B ^d   Crooks, Valerie C ^d   Rosenberg, Lynn ^e   Zandi, Peter P ^f   Breitner, John C S ^f   Resnick, Susan M ^g   Henderson, Victor W ^h  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Voyager Pharmaceutical Corporation   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d KAISER PERMANENTE MEDICAL CENTER   (United States)

^e BOSTON UNIVERSITY   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g NATIONAL INSTITUTE ON AGING   (United States)

^h UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ESTROGEN; FOLLITROPIN; GESTAGEN; GONADOTROPIN; LUTEINIZING HORMONE; MULTIVITAMIN; TESTOSTERONE; VITAMIN;

AGE; ALLELE; ALZHEIMER DISEASE; BRAIN FUNCTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG USE; ESTROGEN THERAPY; GONADOTROPIN BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; ISCHEMIC HEART DISEASE; LETTER; LONG TERM CARE; MEDICAL DECISION MAKING; NEUROLOGIC DISEASE; OUTCOMES RESEARCH; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; VITAMIN SUPPLEMENTATION; FEMALE; NOTE; RISK FACTOR; METABOLISM;

ALZHEIMER DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; RISK FACTORS; ESTROGENS; GONADOTROPINS; POSTMENOPAUSE;

EID: 0242578210     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.9.1100-a     Document Type: Letter

References (0)